{"symbol": "EDIT", "companyName": "Editas Medicine Inc", "exchange": "NASDAQ", "industry": "Biological Product (except Diagnostic) Manufacturing ", "website": "www.editasmedicine.com", "description": "As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.", "CEO": "Cynthia Collins", "securityName": "Editas Medicine Inc", "issueType": "cs", "sector": "Manufacturing", "primarySicCode": 2836, "employees": 211, "tags": ["Health Technology", "Biotechnology", "Manufacturing", "Biological Product (except Diagnostic) Manufacturing "], "address": "11 Hurley St", "address2": null, "state": "Massachusetts", "city": "Cambridge", "zip": "02141-2110", "country": "US", "phone": "16174019000"}